US Stock Insider Trading | Rapid Micro disclosed three insider trading transactions on March 12

K-LinePoet · 2026-04-09T11:14:51+00:00

Rapid Micro (RPID) disclosed three insider transactions on March 12, 2026, including Director Spignesi selling 17.9k shares on March 11, and executives Wilson and WIRTJES also conducted selling transactions on the same day. These transactions reflect the executives' and directors' views on the company's stock price and market trends.

K-LinePoet

2026-04-09 11:14:51

Abstract generation in progress

On March 12, 2026, Rapid Micro (RPID) disclosed three insider trading transactions. Director Spignesi Robert G. Jr. sold 17.9k shares on March 11, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 12, 2026	Director	Spignesi Robert G. Jr.	March 10, 2026	Sell	17.9k	4.11	73.7k
March 12, 2026	Executive	Wilson John J. Addington	March 11, 2026	Sell	9,603	4.32	41.5k
March 12, 2026	Executive	WIRTJES SEAN M	March 11, 2026	Sell	7,480	4.32	32.3k
March 2, 2026	Director	RICCIARDI NATALE S	February 27, 2026	Buy	842	0.75	631.50
February 20, 2026	Executive	Wilson John J. Addington	February 20, 2026	Sell	5,403	3.92	21.2k
February 20, 2026	Director	Spignesi Robert G. Jr.	February 19, 2026	Sell	38.3k	3.89	148.9k
February 20, 2026	Executive	WIRTJES SEAN M	February 20, 2026	Sell	17.3k	3.92	67.7k
February 10, 2026	Director	Spignesi Robert G. Jr.	February 9, 2026	Sell	12.8k	3.78	48.6k
February 10, 2026	Executive	Wilson John J. Addington	February 9, 2026	Sell	4,610	3.78	17.4k
February 10, 2026	Executive	WIRTJES SEAN M	February 9, 2026	Sell	6,027	3.78	22.8k

【Company Information】

Rapid Micro Biosystems, Inc. was incorporated on December 29, 2006, under Delaware law. The company is an innovative life sciences technology firm providing automation solutions to facilitate efficient manufacturing and rapid, safe release of healthcare products such as biopharmaceuticals, vaccines, cell and gene therapies, and sterile injectables. The company develops, manufactures, and sells proprietary consumables for the Growth Direct system, laboratory information management system (“LIMS”) connection software, and services to address rapid microbial analysis for quality control in the manufacturing of pharmaceuticals, medical devices, and personal care products. The company currently sells products to customers in North America, Europe, and Asia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.